CD47 and autoimmune disease: Targeted drugs related to the above pathways have been developed, among which Hu5F9-G4 and CC-90002 are humanized mAb targeting human CD47, which can selectively eliminate malignant cells expressing CD47, mainly inducing transient anemia and mild neutropenia with no other obvious adverse reactions or autoimmune diseases [29].